Literature DB >> 1390486

Retinopathy of prematurity in surfactant treated infants.

S J Rankin1, T R Tubman, H L Halliday, S S Johnston.   

Abstract

Seventy six babies of less than 1500 g birth weight who had surfactant replacement therapy for severe respiratory distress syndrome were studied to assess the presence and stage of subsequent retinopathy of prematurity (ROP). A control group of 90 babies, matched for birth weight and gestational age, who did not have surfactant therapy were also studied. Threshold ROP or greater was found in 1.7% of the surfactant group and 7.8% of the controls. For the babies of less than 1000 g birth weight 4.0% of the surfactant babies and 16.3% of the controls reached threshold disease or greater. It is concluded that surfactant therapy is not associated with an increased incidence or severity of severe ROP in this preterm population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390486      PMCID: PMC504227          DOI: 10.1136/bjo.76.4.202

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  Treatment of retinal detachment due to retinopathy of prematurity. Documented disappointment.

Authors:  R E Kalina
Journal:  Ophthalmology       Date:  1991-01       Impact factor: 12.079

Review 2.  Oxygen toxicity in the neonatal period.

Authors:  O D Saugstad
Journal:  Acta Paediatr Scand       Date:  1990-10

3.  Epidemiology of retinopathy of prematurity.

Authors:  Y K Ng; A R Fielder; D E Shaw; M I Levene
Journal:  Lancet       Date:  1988-11-26       Impact factor: 79.321

Review 4.  Retinopathy of prematurity: what causes it?

Authors:  G B Avery; P Glass
Journal:  Clin Perinatol       Date:  1988-12       Impact factor: 3.430

5.  Clinical factors associated with retinopathy of prematurity.

Authors:  A Prendiville; W E Schulenburg
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

6.  Two-year follow-up of infants enrolled in a randomized trial of surfactant replacement therapy for prevention of neonatal respiratory distress syndrome.

Authors:  M S Dunn; A T Shennan; E M Hoskins; K Lennox; G Enhorning
Journal:  Pediatrics       Date:  1988-10       Impact factor: 7.124

7.  Retrolental fibroplasia--controlled study of 4 years' experience in a neonatal intensive care unit.

Authors:  V Y Yu; D M Hookham; J R Nave
Journal:  Arch Dis Child       Date:  1982-04       Impact factor: 3.791

  7 in total
  4 in total

Review 1.  Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.

Authors:  L R Wiseman; H M Bryson
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

2.  Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment.

Authors:  P M Pennefather; W Tin; M P Clarke; S Fritz; N P Strong
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

3.  Surfactant replacement therapy: a new risk factor in developing retinopathy of prematurity?

Authors:  J U Termote; N E Schalij-Delfos; D Wittebol-Post; H A Brouwers; B R Hoogervorst; B P Cats
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

Review 4.  Natural vs synthetic surfactants in neonatal respiratory distress syndrome.

Authors:  H L Halliday
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.